Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759421 | 0.85 | PTGDR2 (0.43) | AKR1B1PTGDR2CNR1 | |
| SCHEMBL6763802 | 0.80 | SLC6A4 (0.52) | CYP11B1CYP11B2TDP1MAPT | |
| SCHEMBL6762198 | 0.78 | AGBL2 (0.49) | SMN1; SMN2CYP11B1CYP11B2AKR1B1PTGDR2 | |
| SCHEMBL6761086 | 0.78 | ACKR3 (0.43) | SMN1; SMN2CNR1TDP1TP53MAPT | |
| SCHEMBL4982350 | 0.74 | CYP11B1 (0.51) | CYP11B1CYP11B2TDP1MAPTGAA | |
| SCHEMBL8910954 | 0.74 | MAPT (0.43) | CYP11B1CYP11B2CNR1MAPTGAA | |
| SCHEMBL1444146 | 0.74 | TAAR1 (0.50) | SMN1; SMN2HTTTDP1MAPT | |
| SCHEMBL27139325 | 0.72 | TSHR (0.41) | SMN1; SMN2HTTTDP1MAPT | |
| SCHEMBL11359843 | 0.68 | TAAR1 (0.49) | SMN1; SMN2HTTTDP1MAPT | |
| SCHEMBL10438855 | 0.68 | CYP4F2 (0.58) | SMN1; SMN2HTTTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192680-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-09-30 | — | — | US | disclosed |
| WO-2004060859-A2 | NOVEL AMIDES THAT ACTIVATE SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040121994-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121994-A1 | Novel amides that activate soluble guanylate cyclase | GUCY1A1, GUCY1B1, GUCY1A2 | SMN1; SMN2 710/4885HTT 4689/4885CYP11B1 336/4885 |
| US-20040192680-A1 | Novel amides that activate soluble guanylate cyclase | GUCY1A1, GUCY1B1, GUCY1A2 | SMN1; SMN2 710/4885HTT 4689/4885CYP11B1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.